Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactiplantibacillus plantarum TJA7
- Development stage
- Preclinical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactiplantibacillus plantarum TJA7 is a specific probiotic strain belonging to the Lactiplantibacillus genus, formerly classified as Lactobacillus plantarum. It is being investigated for its potential therapeutic role in managing Type 2 Diabetes Mellitus (T2DM) and related metabolic dysfunctions. The strain's mechanism of action involves strengthening the intestinal barrier, as evidenced by increased transepithelial electrical resistance (TEER), and promoting the translocation of the short-chain fatty acid butyrate. At the cellular level, TJA7 modulates the gut-pancreas-liver axis by activating key metabolic signaling pathways, including the IRS1/AKT and AMPK/PGC-1α axes, which leads to reduced oxidative stress, enhanced insulin secretion from pancreatic β-cells, and improved hepatic glucose handling. While often studied in combination with phytochemicals like Mulberry Leaf extract, the TJA7 strain independently contributes to metabolic homeostasis through its influence on the gut microbiota and systemic signaling.
- Other names
- Lactiplantibacillus plantarum strain TJA7L. plantarum TJA7
02
Targets
PPARGC1A (Peroxisome proliferator–activated receptor gamma coactivator 1-alpha)AMPK (Adenosine monophosphate–activated protein kinase)IRS1 (Insulin receptor substrate 1)AKT (RAC-alpha serine/threonine-protein kinase)
Beyond the preview
Go deeper on lactiplantibacillus plantarum TJA7.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactiplantibacillus plantarum TJA7.